ProShare Advisors
SYRS

ProShare Advisors’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

ProShare Advisors’s Portfolio SYRS Stock Details SYRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,721
Closed -$21K – 2175
2022
Q1 		$21K Sell
1,721
-409
-19% -$7.32K ﹤0.01% 2173
2021
Q4 		$69K Buy
2,130
+69
+3% +$2.79K ﹤0.01% 2246
2021
Q3 		$92K Sell
2,061
-544
-21% -$26.6K ﹤0.01% 1921
2021
Q2 		$142K Buy
2,605
+493
+23% +$29.2K ﹤0.01% 2230
2021
Q1 		$158K Buy
2,112
+485
+30% +$50.4K ﹤0.01% 2094
2020
Q4 		$176K Buy
1,627
+381
+31% +$34.8K ﹤0.01% 1883
2020
Q3 		$110K Sell
1,246
-49
-4% -$5.57K ﹤0.01% 1516
2020
Q2 		$138K Buy
+1,295
New +$116K ﹤0.01% 1530
2020
Q1 		– Sell
-1,388
Closed -$96K – 1632
2019
Q4 		$96K Sell
1,388
-156
-10% -$9.46K ﹤0.01% 1695
2019
Q3 		$160K Buy
1,544
+38
+3% +$3.59K ﹤0.01% 1481
2019
Q2 		$139K Buy
1,506
+88
+6% +$6.13K ﹤0.01% 1499
2019
Q1 		$130K Buy
1,418
+11
+0.8% +$766 ﹤0.01% 1544
2018
Q4 		$78K Buy
+1,407
New +$107K ﹤0.01% 1501

Other funds holding SYRS

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
ABG
Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ProShare Advisors's SYRS Position: Q2 2022 in Review

ProShare Advisors sold out of Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q2 2022, closing a stake of 1,721 shares — an estimated $21K sold.

ProShare Advisors first reported a position in SYRS in Q4 2018 and held it in 13 quarters. The position peaked at $176K in Q4 2020. 67 funds tracked by Wall St. Rank hold SYRS as of Q2 2022.

  • ProShare Advisors reported no remaining Syros Pharmaceuticals, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • ProShare Advisors sold 1,721 Syros Pharmaceuticals, Inc. Common Stock shares in Q2 2022, an estimated $21K.
  • ProShare Advisors first reported a position in Syros Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 13 quarters.
  • ProShare Advisors's Syros Pharmaceuticals, Inc. Common Stock position peaked at $176K in Q4 2020.
  • 67 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q2 2022.

Based on ProShare Advisors's 13F filing for Q2 2022, filed 1 Aug 2022.